Bay Area man is hospitalized with rare blood clot after J&J vaccination

SAN FRANCISCO —  A Bay Area man in his 30s is recuperating after developing a rare blood clot in his leg within two weeks of receiving the Johnson & Johnson vaccine, UC San Francisco officials said Monday.

As of last Friday, the U.S. Centers for Disease Control and Prevention had reported the condition in 15 people, all women, after 8 million doses were administered nationally. It involves unusual clots that occur together with low levels of blood-clotting platelets.

“To the best of our knowledge, this is the first male patient with VITT syndrome in the U.S. following the U.S. emergency authorization of the Johnson & Johnson vaccine on Feb. 27,” the university said in a statement.

U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson’s single-dose shot on Friday, after scientific advisors decided its benefits outweigh the very rare risk of blood clot. Three of the women previously identified died, and seven remain hospitalized.

The man is making good progress and should be discharged within a few days, UC San Francisco said in a statement. He was admitted April 21 with escalating pain in his lower back and leg 13 days after receiving the vaccine.

Dr. Andrew Leavitt, a hematologist who is treating the patient, said Monday that a calling card of the syndrome is blood clots in unusual places, such as the head or abdominal areas.

Initial imaging did not show a blood clot, he said, “but much of his clinical picture made us think he was having a clot.”

They eventually found one, and Leavitt said the case sheds light on an emerging and rare condition.

Bloodwork showed the man had the same syndrome as the other patients, although initial imaging did not show a blood clot, university spokeswoman Suzanne Leigh said. Physicians later discovered a tiny clot, she said.

As it recommended resuming J&J vaccinations, the FDA updated its online vaccine information leaflets for would-be recipients and health workers.

Federal health officials say the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative as it has important advantages for some people who were anxiously awaiting its return.